Table 3.
Model | Strategy | Strengths | Weaknesses |
---|---|---|---|
Inflammagen model | LPS co-administration | Easy to use | Poor resemblance to human IDILI |
Uetrecht-Pohl model | Compromised immune tolerance | Time course and pathology resemble human IDILI | No liver failure |
Subclinical mitochondriopathy | Compromised ROS defense | Time course resembles human IDILI | Poor reproducibility |